Your browser doesn't support javascript.
loading
Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin.
Kasichayanula, S; Liu, X; Griffen, S C; Lacreta, F P; Boulton, D W.
Affiliation
  • Kasichayanula S; Discovery Medicine & Clinical Pharmacology, Bristol-Myers Squibb, Princeton, NJ, USA. sreeneeranj.kasichayanula@bms.com
Diabetes Obes Metab ; 15(3): 280-3, 2013 Mar.
Article in En | MEDLINE | ID: mdl-23061428

Full text: 1 Database: MEDLINE Main subject: Rifampin / Mefenamic Acid / Glucuronosyltransferase / Diabetes Mellitus, Type 2 / Enzyme Inhibitors / Sodium-Glucose Transporter 2 Inhibitors / Glucosides / Hypoglycemic Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2013 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Rifampin / Mefenamic Acid / Glucuronosyltransferase / Diabetes Mellitus, Type 2 / Enzyme Inhibitors / Sodium-Glucose Transporter 2 Inhibitors / Glucosides / Hypoglycemic Agents Type of study: Clinical_trials Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2013 Type: Article Affiliation country: United States